Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution

S. Venkatesan1,2†, R. Rosenthal1†, N. Kanu1, N. McGranahan1, J. Bartek3,4,5, S. A. Quezada1,6, J. Hare7, R. S. Harris8,9,10,11,12*‡ & C. Swanton1,2*‡

1CRUK Lung Cancer Centre of Excellence, UCL Cancer Institute, London; 2Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London, UK; 3Danish Cancer Society Research Center, Copenhagen, Denmark; 4Science for Life Laboratory, Stockholm; 5Division of Genome Biology, Department of Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden; 6Cancer Immunology Unit, UCL Cancer Institute, London, UK; 7International AIDS Vaccine Initiative (IAVI), New York; 8Masonic Cancer Center, Minneapolis; 9Institute for Molecular Virology, Minneapolis; 10Center for Genome Engineering, Minneapolis; 11Department of Biochemistry, Molecular Biology and Biophysics; 12Howard Hughes Medical Institute, University of Minnesota, Minneapolis, USA

*Correspondence to: Prof. Reuben S. Harris, Howard Hughes Medical Institute, University of Minnesota, Minneapolis, MN 55455, USA. Tel: +1-612-624-0457; Fax: +1-612-625-2163; E-mail: rsh@umn.edu
Prof. Charles Swanton, Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. Tel: +44-0-2072693463; Fax: +44-0-2072693463; E-mail: charles.swanton@crick.ac.uk
†Both authors contributed equally as first authors.
‡Both authors contributed equally as senior authors.

Introduction

Apolipoprotein B mRNA-editing, catalytic polypeptide-like (APOBEC) mutational signature has only recently been detected in a multitude of cancers through next-generation sequencing. Independent approaches including analyses of next-generation sequencing data implicated APOBEC-catalysed DNA damage and mutagenesis in breast cancer [1, 2]. Subsequent studies confirmed and extended the involvement of APOBEC in mutating the cancer genome to at least 16 other cancer types [3–5]. APOBEC signature mutations (C-to-T and C-to-G in TCA and TCT trinucleotide motifs) are the most prevalent in cancer after those attributable to ageing (C-to-T in CG dinucleotide motifs, most likely due to water-mediated deamination of methylcytosine) [4]. Furthermore, the clinical relevance of APOBEC in cancer is underscored by associations with poor patient outcomes and treatment resistance [6, 7], activation of oncogenic drivers [8–10], tumour subclonal diversification [9, 11, 12], and increased prevalence in metastases in comparison with primary tumours [13].

Although involvement of APOBEC mutagenesis in cancer has only recently come to light, these enzymes have been a focus of virology research for over a decade, beginning with the near simultaneous discoveries of APOBEC3G (A3G) as an HIV-1 restriction factor and as a DNA cytosine deaminase [14, 15] (reviewed elsewhere [16, 17]). We envision that many lessons learnt regarding APOBEC within virology are likely to be applicable to cancer. In this review, we explore the parallels between the role of APOBEC enzymes in HIV and cancer evolution. We discuss data supporting the role of APOBEC mutagenesis in creating HIV genome heterogeneity, drug resistance, and immune escape variants. We hypothesize similar functions of APOBEC will also hold true in cancer.

Key words: APOBEC, immune escape, drug resistance, human immunodeficiency virus, intratumour heterogeneity
APOBEC mutagenesis increases subclonal diversity

APOBEC mutagenesis occurs independently within single cancer cells and viruses, often resulting in strand-coordinated hypermutations (sometimes referred to as kataegis [1]). Evidence for A3B upregulation has been found in over half of all cancers [3] (reviewed elsewhere [31]). Additionally, our groups and others have identified APOBEC activity as contributing to branched evolution and the acquisition of subclonal mutations later in the evolutionary course of lung adenocarcinoma, estrogen receptor (ER)-negative breast cancer, head and neck squamous cell carcinoma, and esophageal adenocarcinomas [11, 35, 36]. A recent analysis of the intratumour heterogeneity present in 100 TRACERx patients with untreated surgically resected primary non-small-cell lung cancer revealed a significant correlation between frequencies of APOBEC signature mutation and the overall number of subclonal mutations [9]. Furthermore, in 19 patients, subclonal driver events were detected as occurring in the APOBEC mutational context [9] (Figure 1A). Moreover, tumours with the largest number of subclonal mutations had extensive evidence of APOBEC mutational signatures, suggesting that APOBEC activity is a strong mutagenic force late in cancer evolution (Figure 1B and C). Subclonal mutations generated from APOBEC activity could potentially drive cancer evolution by enabling the acquisition of late driver mutations. Across multiple types of cancer, there is evidence that APOBEC mutagenesis is responsible for creating driver mutations [5, 8, 9, 12, 31]. The most striking examples are two helical domain hot spot mutations in PIK3CA in papillomavirus-positive head and neck squamous cell carcinomas (E542K and E545K) [8].

APOBEC expression has also been reported to impact responses to cancer therapy. In ER-positive breast cancer, A3B mRNA expression levels inversely correlated with clinical benefit to tamoxifen, and A3B overexpression correlated with tamoxifen resistance in mouse xenograft models, implicating the enzyme in promoting drug resistance [6]. Similarly, an enrichment of A3B mutations was observed in chemotherapy-resistant urothelial carcinomas [37].

APOBEC-induced mutagenesis is also prevalent in HIV-1 proviral DNA sequences [38], with some reports estimating the percentage of new mutations attributable to APOBEC activity to be as high as 98% [39]. However, other studies have estimated lower contributions for APOBEC in HIV-1 genetic variation, and definitive work has yet to be done to dissociate the contributions of APOBEC from mistakes made by the non-proofreading viral reverse transcriptase [38, 40]. Nevertheless, APOBEC activity has been linked to early diversification in newly infected individuals as the transmitted founder virus adapts in response to the immune pressure exerted within its new host [41]. Thus, APOBEC mutagenesis has the capability to increase subclonal diversity in both cancer and HIV, with the potential for a profound impact on the subsequent evolution of both the tumour and the virus (Figure 2).

The fact that APOBEC increases diversity is likely to be important for the clinical course of both diseases, since genetic heterogeneity is a substrate for Darwinian evolution and is likely to confound treatments. Indeed, in some cancers, increased intratumour heterogeneity has been shown to correlate with a shorter progression free survival [42, 43]. Additionally, measures of genetic heterogeneity have been associated with poor progression free survival in cancer [44] and intermediate thresholds of copy number instability correlate with poorest clinical outcomes [31], as they presumably allow for diversity without exceeding toxic levels of genomic instability (Figure 2). Paralleling findings in

A3G has been studied intensely in the field of virology, as it was recognized early on to deaminate cytosines in cDNA reverse transcription intermediates of retroviruses including HIV-1 [24, 25]. Reverse transcriptase places an adenine opposite to the newly created uracil nucleobase, introducing a viral genomic strand G→A mutation [26]. This inhibits HIV replication by directly rendering the viral genome dysfunctional or by indirectly triggering viral cDNA degradation by subsequent uracil DNA glycosylase activity and endonuclease digestion [26, 27]. A3G can also directly bind to HIV-1 genomic RNA and interfere with viral cDNA synthesis [28]. A3D, A3F, and A3H also contribute to HIV-1 mutagenesis through similar mechanisms, and it is generally accepted that different subsets of A3 family members restrict the replication of different classes of viruses and transposons (reviewed elsewhere [16, 17]).

Adding to the complexity of seven A3 family members in humans, different subsets of A3 enzymes are expressed in different tissue types [29, 30]. Together with high levels of DNA sequence similarity (near perfect identity in many regions), determining which of these enzymes is responsible for mutagenesis of different cancer genomes has been challenging. Thus far, the greatest numbers of publications support A3B and A3A (reviewed more extensively elsewhere [31–33]). However, recent reports indicate that A3H is also important and, together with A3B, may account for the entire APOBEC mutation signature observed in breast and lung cancers [34, 35].
Figure 1. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) mutagenesis within the TRACERx 100 cohort. (A) Phylogenetic trees of TRACERx patients harbouring a subclonal driver mutation in an APOBEC preferred motif are shown. The mutation is indicated near the clone in which it occurs. Clonal clusters are shown in blue, subclonal clusters are shown in red, and subclonal clusters containing the driver mutation in a preferred APOBEC motif are shown in orange. (B) The total numbers of mutations in each patient are shown, with mutations in an APOBEC context shown in orange and all other mutational contexts shown in green. (C) The total number of driver mutations in each patient are shown, with mutations in an APOBEC context shown in orange and all other mutational contexts shown in green. (D) The fraction of subclonal mutations for each patient that could be attributed to APOBEC activity are shown, with mutations in an APOBEC context shown in orange and all other mutational contexts shown in green.
cancer, among patients with HIV exhibiting rapid disease progression, there are fewer hypermutated viral sequences as well as fewer minimally edited sequences, suggesting that suboptimal APOBEC activity may enhance genetic diversity, allowing an increase in pathogenicity [39] (Figure 2). From a clinical standpoint, this suggests that successful and complete inhibition of APOBEC enzymatic activity may provide a way to limit subclone diversification and potentially enable normal adaptive immune responses to control or clear HIV-1 infection [45]. Conceivably, complete inhibition of APOBEC enzymatic activity may limit tumour evolution and boost the efficacy of a variety of targeted or immune therapies that often fail due to the acquisition of escape variants brought about by resistance mutations and/or subclonal neoantigens.

Additional lessons from HIV: APOBEC mutagenesis fuels drug resistance and immune escape

In order for HIV and cancer to replicate effectively in human hosts, these pathogenic entities must constantly avoid detection and destruction by innate and adaptive immune responses. As a consequence of this predator–prey relationship, lentiviruses and cancer have evolved elegant mechanisms to avoid or actively counteract immune responses. One of these overlapping mechanisms between HIV and cancer appears to entail co-opting APOBEC mutagenesis as a means of immune evasion.

Lentiviruses and host A3 genes have co-evolved for millions of years in non-human primate relatives [46] and more recently in humans [47]. HIV-1, as well as other lentiviruses, has adapted to suppress A3-mediated innate anti-viral activity through utilizing the viral infectivity factor (Vif) as a defensive measure [15, 25]. Vif counteracts A3 functionality by polyubiquitination and proteasomal degradation [48]. Additionally, Vif has been shown to affect A3G translation through mRNA binding [49] and A3G gene transcription through heterodimerization with the transcription co-factor CBF-β [50]. These discoveries indicate that targeting the Vif-APOBEC3 interaction may be a novel avenue to combat HIV infection. However, over a decade of virology research into the A3-mediated restriction mechanism has demonstrated that interventions in this pathway may be a double-edged sword. Several studies have found that the range of APOBEC mutagenesis within HIV virions can vary largely. Lethal HIV mutagenesis will be selected against in vivo, and moderate APOBEC mutagenesis appears to induce sublethal variation that fuels viral heterogeneity and immune escape [41, 51–53] (Figure 3). Similar to cancer [54], viral genetic heterogeneity together with an appropriate selective pressure can enable the emergence of resistant populations. Sublethal G→A mutations in the DNA sequence motif preferred by A3G have been observed in drug-resistant HIV variants [55–58] and immune escape variants [38, 41, 51, 53] (Figure 2). Mutations in the APOBEC motif are enriched in cytotoxic T lymphocyte epitopes of HIV, and can result in diminished CD8+T cell responses against previously antigenic epitopes, suggestive of selection as a consequence of...
immune escape [38] (Figure 4). Finally, within cancer there is early evidence that APOBEC correlates with the overexpression of the immune checkpoint molecule PD-L1, potentially contributing to the development of immune exhaustion [59] (Figure 4). Indeed, early clinical trial data suggest that reversing immune exhaustion with an anti-PD-L1 antibody enhances the immune response against HIV in a subset of participants [60].

Some of the evolutionary dynamics that have been identified in HIV in response to therapy resistance also appear to apply to cancer. For example, in HIV-1, the V3 loop of gp120 interacts with the host cellular coreceptor CCR5 in order to gain entry to the cell. CCR5 antagonists bind CCR5 and prevent the entry of CCR5-tropic HIV-1 [61]. A common route of CCR5 antagonist resistance is the emergence of HIV-1 variants using CXCR4 instead of CCR5 as a coreceptor for cellular entry [62, 63]. Independent studies detected minor CCR5 antagonist-resistant variants containing resistance mutations in the APOBEC context at baseline that were rapidly selected through therapeutic selective pressure [55, 56]. Complementary to these in vivo studies, in vitro experiments point towards APOBEC mutagenesis generating subclonal resistance mutations, which are under positive selection during drug exposure [58]. Similarly, in cancer, minor drug resistant variants are rapidly selected upon treatment (reviewed in Schmitt et al. [64]), although the contribution of APOBEC in this process remains to be quantified.

An optimal range of APOBEC mutagenesis may exist for both HIV and tumour evolution (Figure 2). It has been shown that several Vif mutants are less potent in inhibiting A3G, with
Vif-K22H incapable of fully neutralizing A3G and therefore appearing to enable sufficient levels of sublethal A3G mutagenesis for the emergence of antiretroviral resistance [57]. Thus, it appears that suboptimal A3G mutagenesis is less effective in inactivating the viral genome and in contrast may promote drug resistance and immune escape [38, 45, 58]. There are also parallels in the context of APOBEC mutagenesis of the cellular genome. Extensive A3B and A3A mutagenesis induces a DNA damage response (DDR) and at excessive levels it is toxic to the cell [2, 65–69]. Therefore, similar to HIV, cancer cells may have to attenuate APOBEC mutagenesis, enhance repair mechanisms, and/or dampen the DDR pathways to help ensure optimal cell survival (Figure 2). For instance, the loss of p53 enables DNA damage tolerance to A3B-mediated mutagenesis [65] and correlates positively with A3B overexpression in breast cancer [2]. Furthermore, a recent report focusing on Y-family polymerases and PrimPol, a translesion synthesis polymerase with re-priming properties, found that PrimPol as well as POLK and POLI may serve to limit the detrimental effects of APOBEC mutagenesis [70].

In addition to sublethal APOBEC mutagenesis driving tumour heterogeneity, APOBEC has recently also been shown to produce replication stress in cancer [65, 71, 72]. This complements our previous observation that replication stress itself can drive A3B expression and activity [73], which suggests a positive feedforward loop involving replication stress and APOBEC mutagenesis (Figure 5). We have previously implicated replication stress in

Figure 4. APOBEC mutagenesis promotes HIV immune escape and potentially also that of cancer. APOBEC mutations have been identified in cytotoxic T lymphocyte epitopes of HIV. APOBEC hypermutation has been linked to PD-L1 ligand overexpression and potentially contributes to immune exhaustion of tumour infiltrating lymphocytes. Studies within the HIV literature are suggestive of sublethal APOBEC mutagenesis driving the expansion of escape variants.
inducing a widespread endogenous DDR as a biological barrier to tumour progression [74–76], as well as driving chromosome segregation errors and ensuing chromosomal instability (CIN) [76, 77]. It is therefore conceivable that oncogene-induced and APOBEC-induced replication stress itself is a driver of CIN in cancer. Furthermore, APOBEC may provide a cancer cell the necessary genomic plasticity to evade immune surveillance. Firstly, a large subclonal neoantigen burden has been associated with a poor response to immunotherapy [78] and conceivably APOBEC-induced subclonal neoantigens may contribute to this process. Although the mechanism of how subclonal neoantigens potentially confound the response to immunotherapy is still unclear, it is conceivable that subclonal neoantigens foster the outgrowth of T cells that are reactive towards subclonal neoantigens that outcompete T cells reactive towards clonal neoantigens. This may result in the outgrowth of T cells that are only reactive to a proportion of the tumour population, diminishing chances of total tumour control. Secondly, ongoing chromosome missegregations (i.e. CIN) may enable the dynamic loss of immunogenic clonal neoantigens [79]. In effect, CIN-mediated loss of clonal neoantigens (provided these mutations are not required for tumour fitness) as well as the acquisition of subclonal neoantigens (due to APOBEC activity) could both aid immune evasion. Interestingly, highly aneuploid (i.e. an abnormal state of chromosomal copy number) tumours have less immune infiltration and are associated with a worse patient survival than less aneuploid tumours [80, 81]. It is yet to be quantified to which extent APOBEC-induced replication stress and potential ensuing CIN contributes to the process of immune evasion.

**Therapeutic considerations**

By analogy to hypermutation and hypomutation within HIV [45], there are at least two general strategies for targeting APOBEC in cancer. The first strategy is therapy by hypermutation, by enhancing the mutagenic effects of APOBEC to the point where cancer cells suffer catastrophic levels of DNA damage and selectively die. Indeed, recent studies have suggested that DDR inhibitors, such as PARP and ATR inhibitors, may sensitize tumour cells with high levels of APOBEC to an APOBEC-dependent death [65, 71, 72].

The second strategy is therapy by hypomutation, by inhibiting APOBEC-dependent tumour evolution and potentially suppressing adverse outcomes including recurrence, metastasis, and drug resistance. Constraining cancer evolvability may be accomplished with drugs to inhibit APOBEC gene expression [73, 82] or with chemical inhibitors of DNA deaminase activity (for exemplary studies on A3G see [83–85]). Proof of principle has been achieved with a genetic knockdown of A3B causing an improvement in the durability of tamoxifen treatment of ER+ xenograft tumours in mice [6].

Besides harnessing APOBEC through a cancer cell intrinsic mechanism, a complementary strategy may be provoking immune responses to cancer cells with high levels of APOBEC-induced neoantigens. It is important to consider whether neoantigens are present in the trunk of the tumour (clonal) or in the branches (subclonal), since clonal neoantigens may improve response to immune checkpoint blockade in contrast to subclonal neoantigens [78]. Interestingly, one APOBEC-mediated mutational signature (signature 2) is primarily found in the branches of multiple different cancer types [12]. In contrast, the other APOBEC-mediated mutational signature (signature 13) is primarily found in the trunk of bladder cancer [12]. This could potentially explain paradoxical effects of APOBEC mutagenesis on immune surveillance and patient outcome. For example, in breast cancer, A3B expression is reported to worsen overall patient survival [6, 7]. In contrast, APOBEC mutagenesis within bladder cancer has been correlated with an improved patient outcome [86, 87], although the influence of APOBEC on survival in bladder cancer is still a matter of debate [88]. Therefore, it is conceivable that patients with tumours containing extensive clonal APOBEC mutagenesis, in contrast to subclonal APOBEC mutagenesis, are more suitable for immune checkpoint blockade.

It is also important to note that several APOBEC family members including A3G and A3H are highly expressed in immune cells, including tumour infiltrating T cells, and correlated with improved outcomes [89, 90]. Thus, as studies advance, it will be crucial to not only consider APOBEC expression and mutation signature in the tumour itself, but also APOBEC expression in the larger tumour microenvironment. Immunohistochemistry approaches would be ideal to help address these relationships, but specific monoclonal antibodies for each human APOBEC family member have been challenging to develop due to extensive protein similarity.

**Discussion**

**Conclusions**

Despite the numerous studies that have detected APOBEC-associated mutations by sequencing clinical cancer samples, it is
still not fully clear why APOBEC mutagenesis is such a widespread and recurring mutational signature. In this review, we have postulated functions of APOBEC in cancer through exploring the past virology research focused on HIV and APOBEC. Within the field of virology, sublethal APOBEC mutagenesis of HIV virions has been linked to increasing HIV diversity and the creation of drug and immune escape variants. Conceivably, similar functions for APOBEC mutagenesis may be operating, and be selected for, during cancer evolution with clear opportunities for the development of novel therapeutic interventions.

**Funding**

This work was partially funded from Cancer Research UK, Rosetrees and the University College London Hospitals Biomedical Research Centre (NM); the Danish Cancer Society, Swedish Research Council, NovoNordisk Foundation (ID 16584), Danish National Research Foundation (project CARD) and Danish Council for Independent Research (JB); IAVI with the generous support of USAID and other donors (JH) (a full list of IAVI donors is available at www.iavi.org); grants from the National Institutes of Health (NIAID R37 AI064046 and NCI R21 CA206309 (RSH)).

This work was supported by Cancer Research UK (TRACERx), the Rosetrees Trust, NovoNordisk Foundation (ID 16584), EU FP7 (projects PREDICT and RESPONSIFY, ID number 259303), the Prostate Cancer Foundation, the Breast Cancer Research Foundation, the European Research Council (THESEUS), and National Institute for Health Research University College London Hospitals Biomedical Research Centre (CS). The contents of this manuscript are the responsibility of the authors and do not necessarily reflect the views of USAID or the US Government. RSH is the Margaret Harvey Schering Land Grant Chair for Cancer Research, a Distinguished McKnight University Professor, and an Investigator of the Howard Hughes Medical Institute.

This work was supported by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC001169), the UK Medical Research Council (FC001169), and the Wellcome Trust (FC001169).

**Disclosure**

RSH is a co-founder, consultant, and shareholder of ApoGen Biotechnologies Inc.

CS is a member of the advisory board of ApoGen Biotechnologies Inc. All remaining authors have declared no conflicts of interest.

**References**

1. Nik-Zainal S, Alexandrov LB, Wedge DC et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 149(5): 979–993.
2. Burns MB, Lackey L, Carpenter MA et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013; 494: 366–370.
3. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 2013; 45(9): 977–983.
4. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 2013; 500(7463): 415–421.
5. Roberts SA, Lawrence MS, Klimczak LJ et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013; 45(9): 970–976.
6. Law EK, Sieuwerts AM, LaPara K et al. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci Adv 2016; 2: e1601737.
7. Sieuwerts AM, Willis S, Burns MB et al. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm Cancer 2014; 5(6): 405–413.
8. Henderson S, Chakravarty A, Su X et al. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 2014; 7: 1833–1841.
9. Jamal-Hanjani M, Wilson GA, McGranahan N et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med 2017; 376(22): 2109–2121.
10. Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services et al. Integrated genomic and molecular characterization of cervical cancer. Nature 2017; 543: 378–384.
11. de Bruin EC, McGranahan N, Mitter R et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014; 346: 251–256.
12. McGranahan N, Favela F, de Bruin EC et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med 2015; 7: 283ra254.
13. Lefèvre C, Bachelor T, Filleron T et al. Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med 2016; 13: e1002201.
14. Harris RS, Petersen-Mahrt SK, Neuberger MS. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell 2002; 10(5): 1247–1253.
15. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418(6898): 646–650.
16. Harris RS, Dudley JP. APOBECs and virus resistance. Virology 2015; 479–480: 131–145.
17. Simon V, Bloch N, Landau NR. Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat Immunol 2015; 16(6): 546–553.
18. Furumatsu M, Kinoshita K, Fagarasan S et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000; 102(5): 553–563.
19. Navaratnam N, Morrison JR, Bhattacharya S et al. The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase. J Biol Chem 1993; 268(28): 20709–20712.
20. Severi F, Chicca A, Conticello SG. Analysis of reptilian APOBEC1 suggests that RNA editing may not be its ancestral function. Mol Biol Evol 2011; 28: 1125–1129.
21. Conticello SG. The AID/APOBEC family of nucleic acid mutators. Genome Biol 2008; 9(6): 229.
22. LaRue RS, Jönsson SR, Silverstein KA et al. The artiodactyl APOBEC family immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol Biol 2008; 9: 104.
23. Sawyer SL, Emerman M, Malik HS. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol 2004; 2: E275.
24. Mangeat B, Turelli P, Caron G et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424(6944): 99–103.
25. Zhang H, Yang B, Pomerantz RJ et al. The cytidine deaminase CEM15 induces hypermethylation in newly synthesized HIV-1 DNA. Nature 2003; 424(6944): 94–98.
26. Harris RS, Bishop KN, Sheehy AM et al. DNA deamination mediates innate immunity to retroviral infection. Cell 2003; 113(6): 803–809.
27. Weil AF, Ghosh D, Zhou Y et al. Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration. Proc Natl Acad Sci U S A 2013; 110: E448–E457.

28. Holmes RK, Koning FA, Bishop KN, Malin MH. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 2007; 282: 2587–2595.

29. Refsdal EW, Stenglein MD, Shindo K et al. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 2010; 38(13): 4274–4284.

30. Koning FA, Newman EN, Kim EY et al. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 2009; 83: 9474–9485.

31. Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov 2015; 5(7): 704–712.

32. Helleday T, Eshtad S, Nik-Zainal S. Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet 2014; 15: 585–598.

33. Roberts SA, Gordenin DA. Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer 2014; 14(12): 786–800.

34. Zhu M, Wang Y, Wang C et al. The eQTL-missense polymorphisms of APOBEC3H are associated with lung cancer risk in a Han Chinese population. Sci Rep 2015; 5: 14969.

35. Faltas BM, Prandi D, Tagawa ST et al. Clonal evolution of chemotherapy-resistant uterine cervical cancer. Nat Genet 2016; 48: 1490–1499.

36. Kim EY, Lorenzo-Redondo I, Little SJ et al. Human APOBEC3 induced mutation of human immunodeficiency virus type 1 contributes to adaptation and evolution in natural infection. PLoS Pathog 2014; 10: e1004281.

37. Cuevas JM, Geller R, Garijo R et al. Extremely high mutation rate of HIV-1 in vivo. PLoS Biol 2015; 13(9): e1002251.

38. Delvixks-Frankenberry KA, Nikolaitchik OA, Burdick RC et al. Minimal contribution of APOBEC3-induced G-to-A hypermutation to HIV-1 recombination and genetic variation. PLoS Pathog 2016; 12(5): e1005646.

39. Wood N, Bhattacharya T, Keele BF et al. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 2009; 5(5): e1000414.

40. Birkbak NJ, Eklund AC, Li Q et al. Positioning of APOBEC3-F and G in the human genome. Genome Biol 2016; 17: 31.

41. Andor N, Graham TA, Jansen M et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nature 2016; 534: 105–113.

42. Schwarz RF, Ng CKY, Cooke SL et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med 2015; 12(2): e1001789.

43. Compton AA, Emerman M. Convergence and divergence in the evolution of the APOBEC3G-Vif interaction reveal ancient origins of simian immunodeficiency viruses. PLoS Pathog 2013; 9: e1003135.

44. Nakano Y, Misawa N, Juarez-Fernandez G et al. HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation. PLoS Pathog 2017; 13: e1006348.

45. Mercenier G, Bernacchi S, Richer D et al. HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Res 2010; 38(2): 633–646.

46. Anderson BD, Harris RS. Transcriptional regulation of APOBEC3 antiviral immunity through the CBF-beta/RUNX axis. Sci Adv 2015; 1: e1500296.

47. Squires K, Monajemi M, Woodworth CF et al. Impact of APOBEC mutations on CD8+ T cell recognition of HIV epitopes varies depending on the restricting HLA. J Acquir Immune Defic Syndr 2015; 70(2): 172–178.

48. Sailer HA, Stenglein MD, Harris RS, Mansky LM. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol 2010; 84: 7396–7404.

49. Monajemi M, Woodworth CF, Zipperlen K et al. Positioning of APOBEC3G/F mutational hotspots in the human immunodeficiency virus genome favors reduced recognition by CD8+ T cells. PLoS One 2014; 9: e93428.

50. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481(7381): 306–313.

51. Toda S, Amor D, Arnaout R et al. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 2009; 4: e6863.

52. Todesco E, Burgers I, Marcelin AG et al. Presence of minority resistant variants after failure of a tenofovir, emtricitabine, and rilpivirine regimen. J Acquir Immune Defic Syndr 2016; 72: e43–e45.

53. Fazioli F, Maltei I, Binka M et al. Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. AIDS 2010; 24(15): 2313–2321.

54. Kim EY, Bhattacharya T, Kunstman K et al. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J Virol 2010; 84: 10402–10405.

55. Beichert A, Tsigelny IF, Kurzrock R. High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations. Oncoimmunology 2017; 6: e1284719.

56. Gay CL, Bosch RJ, Ritz J et al. Clinical trial of the Anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy. J Infect Dis 2017; 215(11): 1725–1733.

57. Strizki JM, Tremblay C, Xu S et al. Discovery and characterization of virci-virotic (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005; 49: 4911–4919.

58. Fäkkenheuer G, Nelson M, Lazzarin A et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359: 1442–1455.

59. Westby M, Lewis M, Whitcomb J et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80: 4909–4920.

60. Schmitt MW, Loeb LA, Salk JJ. The influence of subclonal resistance mutations on targeted cancer therapy. Nat Rev Clin Oncol 2016; 13: 335–347.

61. Nikkilä J, Kumar R, Campbell J et al. Elevated APOBEC3B expression drives a kataegis-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. Br J Cancer 2017; 117: 113–123.

62. Akre MK, Starrett GJ, Quist IS et al. Mutation processes in 293-based clones overexpressing the DNA cytosine deaminase APOBEC3B. PLoS One 2016; 11(3): e0153591.

63. Cavall V, Suspen R, Shapira M et al. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3’UTR enhances chromosomal DNA damage. Nat Commun 2014; 5: 5129.

64. Landry S, Narvaiza I, Linfesty DC, Weitzman MD. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep 2011; 12(5): 444–450.

65. Green AM, Landry S, Budagyan K et al. APOBEC3A damages the cellular genome during DNA replication. Cell Cycle 2016; 15: 998–1008.
70. Pilzecker B, Buoninfante OA, Pritchard C et al. PrimPol prevents APOBEC/AID family mediated DNA mutagenesis. Nucleic Acids Res 2016; 44(10): 4734–4744.

71. Buisson R, Lawrence MS, Benes CH, Zou L. APOBEC3A and 3B activities render cancer cells susceptible to ATR inhibition. Cancer Res 2017; 77(17): 4579–4588.

72. Green AM, Budagyan K, Hayer KE et al. Cytosine deaminase APOBEC3A sensitizes leukemia cells to inhibition of the DNA replication checkpoint. Cancer Res 2017; 77(17): 4579–4588.

73. Kanu N, Cerone MA, Goh G et al. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biol 2016; 17(1): 185.

74. Bartkova J, Horejsi Z, Koed K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434(7035): 864–870.

75. Bartkova J, Rezaei N, Liontos M et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444: 633–637.

76. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319(5868): 1352–1355.

77. Burrell RA, McClelland SE, Endesfelder D et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 2013; 494: 492–496.

78. McGranahan N, Furness AJS, Rosenthal R et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016; 351(6280): 1463–1469.

79. Anagnostou V, Smith KN, Forde PM et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov 2017; 7: 264–276.

80. Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 2017; 355; doi: 10.1126/science.aaf8399.

81. Karn T, Jiang T, Hatzis C et al. Association between genomic metrics and immune infiltration in triple-negative breast cancer. JAMA Oncol 2017; 3(12): 1707–1711.

82. Leonard B, McCann JL, Starrett GJ et al. The PKC/NF-kappaB signaling pathway induces APOBEC3B expression in multiple human cancers. Cancer Res 2015; 75(21): 4538–4547.

83. Li M, Shandilya SMD, Carpenter MA et al. First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem Biol 2012; 7(3): 506–517.

84. Olson ME, Li M, Harris RS, Harki DA. Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1, 2, 4-triazole-3-thiol scaffold. ChemMedChem 2013; 8: 112–117.

85. Olson ME, Abate-Pella D, Perkins AL et al. Oxidative reactivities of 2-furylquinolines: ubiquitous scaffolds in common high-throughput screening libraries. J Med Chem 2015; 58: 7419–7430.

86. Lerner SP, Robertson G, Kim J et al. Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas. J Clin Oncol 2017; 35: 4500–4500.

87. Glaser AP, Fantini D, Rimar KJ, Meeks JJ. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response. bioRxiv 2017.

88. Hedegaard J, Lamy P, Nordentoft I et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 2016; 30: 27–42.

89. Mullan SA, Werner L, Rosenberg J et al. Correlation of APOBEC MRNA expression with overall survival and PD-L1 expression in urothelial carcinoma. Sci Rep 2016; 6: 27702.

90. Leonard B, Starrett GJ, Maurer MJ et al. APOBEC3G expression correlates with T cell infiltration and improved clinical outcomes in high-grade serous ovarian carcinoma. Clin Cancer Res 2017; 22(18): 4746–4755.